Project Details
Description
we propose two translational
objectives embedded in the clinical trial:
Aim 1: Measure the antigen burden induced by
treatment with guadecitabine in human tumors in
relationship to clinical response.
Aim 2: Determine the anti-tumor activity of CD8+
effector T cells induced by treatment with
guadecitabine and pembrolizumab in relationship to
clinical response.
We will take advantage of the unique resource provided by the ready-to-activate investigator initiated phase II
clinical trial testing the combination of pembrolizumab and guadecitabine (SGI-110) in women with platinum
resistant OC and measure tumor antigen expression and immune activation in tumor biopsies obtained before
and after treatment.
| Status | Finished |
|---|---|
| Effective start/end date | 5/1/17 → 4/30/21 |
Funding
- U.S. Army Medical Research and Materiel Command (W81XWH-17-1-0141 P00002)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.